B+
Bull case
25%
Probability
Target price
$37.69
Analysis reference price unavailable
Analysis 2026-08-05 · RankAlpha Sentiment Codex
GMAB
Genmab A/SCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$29.02
Analysis reference price unavailable
Analysis 2026-08-05 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$24.67
Analysis reference price unavailable
Analysis 2026-08-05 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-05
Recent news sentiment (30D)
+45.0
Positive
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+55.2
Score
AI commentary
Recent primary-company news is mixed: positive TEPKINLY approval, DLBCL-4 PFS results, and DARZALEX sales are offset by the DLBCL-1 U.S. overall-survival endpoint miss. Coverage is high, but analyst revisions and post-event market-reaction attribution are unavailable; sentiment is therefore neutral with a cautious monitoring bias.
RankAlpha Sentiment Codex - 2026-08-05
Open full AI memoEvidence flagged
high-coverage report lacks a dated company-specific catalyst beyond generic cadence; peer set is too generic or lacks enough direct operating comparators; memo remains a monitoring view with limited forward evidence and should not be standard-conviction
Impact
tentative
Confidence
-
AI events
2026-06-29catalystDLBCL-4 regulatory and commercial follow-throughHigh impact
The Phase 3 EPCORE DLBCL-4 trial met its PFS objective, reducing progression or death risk by 60% under the U.S. censoring rule; Genmab and AbbVie plan to engage global regulators. [#IR-GMAB-DLBCL4-2026-06-29]
2026-07-06eventEuropean follicular-lymphoma label expansionMedium impact
The European Commission approved TEPKINLY plus lenalidomide and rituximab for relapsed/refractory follicular lymphoma, creating a commercial expansion opportunity supported by positive Phase 3 efficacy data. [#IR-GMAB-TEPKINLY-2026-07-06]
2026-07-23catalystEPCORE DLBCL-1 U.S. overall-survival endpoint miss remains the key overhangHigh impact
Genmab and AbbVie clarified that overall survival was the sole U.S. primary endpoint and was not met, leaving near-term sentiment vulnerable while investors reassess epcoritamab’s confirmatory-data profile. [#IR-GMAB-DLBCL1-2026-07-23]
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-05 • Updated nightlySource: Internal modelMethodology